GATC Health Continues to Receive Strong Media Attention

Irvine, CA—February 10, 2026 – GATC Health received coverage in three leading industry publications last week. On Tuesday, GATC Health’s President Dr. Rahul Gupta was featured in Healthcare Brew, the healthcare arm of the widely read Morning Brew publication. The article focused on opportunities for innovation in biotech amid shifting clinical trial rules announced by the FDA.

On February 4, Dr. Gupta was quoted in a recent BioSpace article examining the FDA’s future as it adapts to the innovation that AI has brought to drug discovery. Dr. Gupta spoke about the challenges that regulatory professionals are facing right now—and how GATC Health’s groundbreaking Operon™ AI platform can help solve these issues—in this ever-evolving landscape.

BiotechTV, a leading biotechnology-centric news outlet recently featured GATC Health’s Chief Business Officer, Tyrone Lam, in an in-depth interview focused on how GATC Health’s collaboration with Lloyd’s of London to provide industry-first clinical trial insurance to biotech’s and their funding partners. GATC Health’s AI is instrumental in helping the underwriters predict the clinical performance of the insured drug candidates, repaying investors in the event that endpoints are not met.

About GATC Health
GATC Health is a tech-bio company revolutionizing drug discovery and development by simulating complex human biology to predict how drugs will perform in the body, achieving 91% specificity and 86% sensitivity. Trusted by the world’s largest insurance marketplace, biopharma, researchers, and investment partners, GATC Health’s risk prediction product, the Derisq™ AI report, accurately assesses and predicts drug candidate safety, efficacy, and non-obvious side effects prior to the commitment of development capital. GATC Health’s Operon™ platform is also generative, creating intellectual property, extending pipelines, and optimizing assets. By uniting advanced AI, multiomics, and predictive modeling, GATC Health accelerates breakthroughs and reduces costly late-stage failures to bring safer, more effective therapies to patients worldwide.